Tiragolumab

Generic Name: Tiragolumab

Brand Names: -

Drug Type: Biotech

Chemical Formula: -

CAS Number: 1918185-84-8

Unique Ingredient Identifier: 6XG22YQM2Z

Background: Tiragolumab is under investigation in clinical trial NCT04513925 (A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)).

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Phase I/Ib Trial of TIraGolumab, AtEzolizumab, and RadScopal Radiation in Patients With Advanced Solid Malignancies (TIGER)

Phase 1

Not yet recruiting

Conditions: Advanced Solid Malignancies

Interventions: Drug: Tiragolumab
Drug: Atezolizumab
Radiation: Radiation Therapy

First Posted Date: 2025-01-06

Last Posted Date: 2025-01-06

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 56

Registration Number: NCT06760481

Locations: 🇺🇸
The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States

A Phase 2 Clinical Trial Evaluating the Efficacy and Safety of Dual Immune Checkpoint Inhibition With Anti-PD-L1 (Atezolizumab) and Anti-TIGIT (Tiragolumab) in Cancer of Unknown Primary

Phase 2

Not yet recruiting

Conditions: Cancer

Interventions: Drug: Atezolizumab
Drug: Tiragolumab

First Posted Date: 2024-12-31

Last Posted Date: 2024-12-31

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 35

Registration Number: NCT06754501

Locations: 🇺🇸
The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States

Immunotherapies in Combination With Stereotactic Body Radiation Radiotherapy in Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC)

Phase 2

Not yet recruiting

Conditions: Microsatellite Stable Metastatic Colorectal Cancer
Metastatic Colorectal Cancer
Colorectal Cancer

Interventions: Biological: Tiragolumab
Biological: Atezolizumab
Radiation: Stereotactic Body Radiation Therapy (SBRT)

First Posted Date: 2024-09-19

Last Posted Date: 2025-01-10

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 36

Registration Number: NCT06603818

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Testing the Combination of Anti-cancer Drugs Tiragolumab and Atezolizumab to Improve Outcomes for Patients With Recurrent Glioblastoma

Phase 2

Withdrawn

Conditions: Recurrent Glioblastoma, IDH-Wildtype

Interventions: Biological: Atezolizumab
Procedure: Biospecimen Collection
Procedure: Magnetic Resonance Imaging
Procedure: Surgical Procedure
Biological: Tiragolumab

First Posted Date: 2024-03-25

Last Posted Date: 2024-12-30

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 52

Registration Number: NCT06328036

A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma

Phase 1

Recruiting

Conditions: Carcinoma, Hepatocellular

Interventions: Drug: Bevacizumab
Drug: Atezolizumab
Drug: Tobemstomig
Drug: Tiragolumab

First Posted Date: 2023-06-18

Last Posted Date: 2025-01-10

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 150

Registration Number: NCT05908786

Locations: 🇺🇸
University of Southern California (USC), Los Angeles, California, United States
🇺🇸
Columbia University Medical Center, New York, New York, United States
🇦🇹
Department of Internal Medicine III AKH and Medical University of Vienna, Vienna, Austria

and more 32 locations

A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (IMbrave152)

Phase 3

Recruiting

Conditions: Carcinoma, Hepatocellular

Interventions: Drug: Atezolizumab
Drug: Bevacizumab
Drug: Tiragolumab
Other: Placebo

First Posted Date: 2023-06-15

Last Posted Date: 2025-01-09

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 650

Registration Number: NCT05904886

Locations: 🇵🇱
ID Clinic, Myslowice, Poland
🇿🇦
Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg, South Africa
🇿🇦
Limpopo Cancer Research Institute, Polokwane, South Africa

and more 229 locations

A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study

Phase 3

Recruiting

Conditions: Cancer

Interventions: Drug: Tiragolumab
Drug: Ipatasertib
Drug: Atezolizumab

First Posted Date: 2023-05-17

Last Posted Date: 2025-01-09

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 60

Registration Number: NCT05862285

Locations: 🇧🇪
GHdC Site Notre Dame, Charleroi, Belgium
🇫🇷
Institut de Cancérologie de Bourgogne, Dijon, France
🇫🇷
Centre Régional de Lutte Contre Le Cancer Val D'aurelle Paul Lamarque, Montpellier, France

and more 21 locations

Testing the Combination of Anti-cancer Drugs Atezolizumab and Tiragolumab in People With Advanced Stage Rare Cancers, RARE3 Trial

Phase 2

Recruiting

Conditions: Advanced Rare Malignant Solid Neoplasm
Rare Malignant Solid Neoplasm
Refractory Rare Malignant Solid Neoplasm

Interventions: Biological: Atezolizumab
Procedure: Biopsy
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: Echocardiography
Drug: Tiragolumab

First Posted Date: 2023-02-08

Last Posted Date: 2025-01-10

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 15

Registration Number: NCT05715281

Locations: 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸
National Cancer Institute Developmental Therapeutics Clinic, Bethesda, Maryland, United States
🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC).

Phase 2

Recruiting

Conditions: Squamous Cell Carcinoma
Oral Cavity Squamous Cell Carcinoma

Interventions: Drug: Tiragolumab
Drug: Atezolizumab
Behavioral: Standard of Care
Behavioral: Questionnaires
Radiation: Cisplatin
Radiation: Carboplatin

First Posted Date: 2023-01-11

Last Posted Date: 2025-01-10

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 29

Registration Number: NCT05681039

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors

Phase 1

Recruiting

Conditions: Recurrent Rhabdoid Tumor
Refractory Epithelioid Sarcoma
Refractory Kidney Medullary Carcinoma
Refractory Malignant Solid Neoplasm
Epithelioid Sarcoma
Malignant Solid Neoplasm
Kidney Medullary Carcinoma
Recurrent Epithelioid Sarcoma
Recurrent Malignant Solid Neoplasm
Refractory Atypical Teratoid/Rhabdoid Tumor

Interventions: Biological: Atezolizumab
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Other: Fludeoxyglucose F-18
Procedure: Magnetic Resonance Imaging
Procedure: Positron Emission Tomography
Biological: Tiragolumab
Procedure: X-Ray Imaging

First Posted Date: 2022-03-18

Last Posted Date: 2024-12-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 86

Registration Number: NCT05286801

Locations: 🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸
Children's Hospital of Orange County, Orange, California, United States

and more 37 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy